| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
|
Schöffski, Patrick
|
|
2012
|
48 |
2 |
p. 179-186
8 p.
|
artikel
|
| 2 |
A phase III trial of docetaxel–estramustine in high-risk localised prostate cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trial
|
Fizazi, Karim
|
|
2012
|
48 |
2 |
p. 209-217
9 p.
|
artikel
|
| 3 |
A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study
|
Yi, Jun Ho
|
|
2012
|
48 |
2 |
p. 196-201
6 p.
|
artikel
|
| 4 |
Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe
|
Trama, A.
|
|
2012
|
48 |
2 |
p. 159-169
11 p.
|
artikel
|
| 5 |
Corrigendum to “Can allogeneic peripheral blood stem cells be safely cryopreserved for use in patients undergoing transplant” [Eur. J. Cancer 47 (S1) (2011) S648]
|
Patel, M.
|
|
2012
|
48 |
2 |
p. 287-
1 p.
|
artikel
|
| 6 |
Decision-making in the end-of-life phase of high-grade glioma patients
|
Sizoo, Eefje M.
|
|
2012
|
48 |
2 |
p. 226-232
7 p.
|
artikel
|
| 7 |
Hepatotoxicity associated with lapatinib in an experimental rat model
|
Demirci, Umut
|
|
2012
|
48 |
2 |
p. 279-285
7 p.
|
artikel
|
| 8 |
How many deaths would be avoidable if socioeconomic inequalities in cancer survival in England were eliminated? A national population-based study, 1996–2006
|
Ellis, Libby
|
|
2012
|
48 |
2 |
p. 270-278
9 p.
|
artikel
|
| 9 |
Nutritional status at diagnosis is related to clinical outcomes in children and adolescents with cancer: A perspective from Central America
|
Sala, Alessandra
|
|
2012
|
48 |
2 |
p. 243-252
10 p.
|
artikel
|
| 10 |
Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma
|
Geoerger, Birgit
|
|
2012
|
48 |
2 |
p. 253-262
10 p.
|
artikel
|
| 11 |
Quantitative monitoring of BCR/ABL1 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia
|
Preuner, S.
|
|
2012
|
48 |
2 |
p. 233-236
4 p.
|
artikel
|
| 12 |
Retraction notice to “Prostate cancer screening in the Tyrol, Austria: Experience and results” [Eur J Cancer 36 (2000) 1322–1335]
|
Horninger, W.
|
|
2012
|
48 |
2 |
p. 286-
1 p.
|
artikel
|
| 13 |
Survival from childhood acute lymphoblastic leukaemia: the impact of social inequality in the United Kingdom
|
Lightfoot, T.J.
|
|
2012
|
48 |
2 |
p. 263-269
7 p.
|
artikel
|
| 14 |
Targeted agents: How to select the winners in preclinical and early clinical studies?
|
Goodwin, Rachel
|
|
2012
|
48 |
2 |
p. 170-178
9 p.
|
artikel
|
| 15 |
The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma
|
Keizman, Daniel
|
|
2012
|
48 |
2 |
p. 202-208
7 p.
|
artikel
|
| 16 |
The efficacy of zoledronic acid in breast cancer adjuvant therapy: A meta-analysis of randomised controlled trials
|
Yan, Tingting
|
|
2012
|
48 |
2 |
p. 187-195
9 p.
|
artikel
|
| 17 |
The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use
|
Hanaizi, Zahra
|
|
2012
|
48 |
2 |
p. 237-242
6 p.
|
artikel
|
| 18 |
Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991
|
Eggermont, Alexander M.M.
|
|
2012
|
48 |
2 |
p. 218-225
8 p.
|
artikel
|
Tijdschrift beschrijving